NAPPA
Leadership

Operators who have lived the cross-border problem.

NAPPA's founding leadership team brings decades of combined experience across U.S. and Chinese biopharma — clinical, commercial, regulatory, and capital.

John Xu, MD, MBA, MS
John Xu, MD, MBA, MS
President
Boston, MA
Two decades in biopharma research, business development, and cross-border licensing. Trained at Shanghai Medical University; 14 years in oncology research at Bristol Myers Squibb and CNS work at Wyeth. Subsequent BD leadership at WuXi AppTec and CrownBio. For the past eight years, has managed licensing transactions between the U.S. and China.
Anna Xu, MD, MBA
Anna Xu, MD, MBA
Vice President
Boston / Vienna
Clinical Pathology and Gynecologic Oncology MD from the Medical University of Vienna; trained at Peking University Health Science Center. Held leadership roles at Vienna General Hospital and served as SVP at Whale Imagine, Inc. Chairs the Global Surgical Doctors Foundation and directs the American Chinese Medical Alliance.
Lucia Yu'e Liu, PhD
Lucia Yu'e Liu, PhD
Secretary General
Boston, MA
PhD and DBA, Harvard postdoctoral training. Expertise in oncology biomarker discovery, RNA therapeutics, and preclinical development. Regulatory background includes IND preparation and FDA eCTD submissions. At NAPPA, evaluates pipeline assets and guides investment decisions while fostering cross-functional collaboration.
Regional leadership

Regional leads anchor NAPPA across global innovation hubs.

Each regional lead connects NAPPA's Boston headquarters to a key biopharma corridor — driving local programming, partner introductions, and cross-border project execution.

BM
Bei Ma
Maryland & Greater DC Regional Head
Founder & CEO, The Pinea Group
20+ years across global life sciences and healthcare. Former VP of Global Healthcare BD at the British Standards Institution; former R&D and Innovation Lead at the United States Pharmacopeia. Appointed by Maryland Governor Wes Moore to the Maryland Venture Fund Authority Board. Connects regulatory, capital, and industry across the NIH/FDA/USP innovation corridor.
YL
Ying Luan, PhD
SF Bay Area Regional Head
Sr. Director, Biostatistics, Olema Oncology
15+ years in global drug R&D across oncology, immunology, and CNS. Career spans GRAIL, AbbVie, Jazz Pharmaceuticals, Teikoku Pharma, and Johnson & Johnson. PhD in Statistics, UC Riverside; MBA, Wharton. Focuses on clinical trial design, regulatory strategy, and cross-border BD diligence.
AC
Alan Chen
Guangdong–HK–Macao Greater Bay Area Regional Head
Executive Director & GM, Guangzhou Shangjun Investment Consulting
Healthcare investor and translational-medicine builder bridging biopharma R&D, capital, and industry across the Guangdong–Hong Kong–Macao Greater Bay Area. Co-manages multiple biopharma industry funds, with deep partnerships across Southern Medical University, Sun Yat-sen University, and Hong Kong-based research institutions.
TT
Tiffany Tse
Hong Kong Regional Head
Founder & MD, Joint PR Consultants; Co-Founder, Bio-Pharma Consulting
Cross-border capital strategist focused on U.S.–Asia biopharma transactions. Leads NewCo structural design, capital fundraising, and IPO pathway planning (including Hong Kong listings) for innovative pharma companies. Executive MBA, Northwestern Kellogg–HKUST.
CF
Chen Feng
Shanghai Regional Head
Founder & CEO, Boren Capital
Pharma investor and asset-trading specialist. Pioneered China's first interactive pharmaceutical asset trading system. 20+ years across senior leadership at Johnson & Johnson, Novartis, Pfizer, and Takeda spanning hematology, immunology, and cardiovascular. Medical degree; MBA, Wharton.
HY
Helen Yang
Beijing Regional Head
Founder, Stellar Glimmer
20+ years across biotech, strategy consulting, private equity, medical media, and industry research. Career includes Beida Weiming Bio, IQVIA, and Warburg Pincus. Education: Peking University Life Sciences; corporate finance and investment management, University of Hong Kong.
OG
Olivia Geng, PhD
Singapore Regional Head
Managing Director, Altea Investments
20+ years across research, commercialization, and strategy in the U.S. and APAC. Built Berkeley Lights' APAC business from 0→1 and led a 200-person U.S. sales team through IPO. PhD, Cornell. Anchors NAPPA's APAC presence across Singapore, Australia, Japan, Korea, and India.
WZ
Wu Zhou
Malaysia, Indonesia & Vietnam Regional Head
Founder & Chairman, Pharmasolution Asia; MD, Chengye Capital
End-to-end pharma market-entry specialist for Southeast Asia, with prior leadership at Pfizer, Daiichi Sankyo, and GSK. Expert in ACTD registration, NPP frameworks, and LPF/SPC capital structures. Master's, Hong Kong Baptist University; EMBA, HKU Business School. Has supported 20+ product launches across the region since 2024.
JJ
Jay Jay
Korea Regional Head
CEO & Founder, IEUM
Multidisciplinary background spanning R&D, clinical development, and BD&L. Prior roles: Managing Director BD&L at NEX-I; Director at AebisBio and SNBioScience; manager at Hanmi Pharm. Hands-on experience across license-out, joint development, and technology-transfer deal structures.
TC
Thomas (Hsiu-Ho) Chou
Taiwan Regional Co-Head
Dual background in genetic counseling and financial investment. Operates at the intersection of science and capital — structuring cross-border licensing deals, guiding companies through IPO readiness, and orchestrating resource integration across Asia–Americas pipelines.
YC
Yi-Fen Cheng
Taiwan Regional Co-Head
Consultant specializing in clinical transformation and AI-enabled drug R&D, supporting startups and pre-IPO firms. Expertise spans molecular diagnostics and strategic business development, providing systematic, end-to-end services from translational strategy to commercialization.

Interested in serving as a regional lead in another corridor? Get in touch.